165 / 172
165
rheumatoid arthritis receiving concomitant methotrexate
therapy: a randomized, placebo-controlled, 52-week trial.
Arthritis Rheum 2004; 50: 1400-11.
162.Keystone EC, Kavanaugh A, Weinblatt ME, Patra K,
Pangan AL. Clinical consequences of delayed addition of
adalimumab to methotrexate therapy over 5 years in patients
with rheumatoid arthritis. J Rheumatol 2011; 38: 855-62.
163.Weinblatt ME, Keystone EC, Furst DE, Moreland LW,
Weisman MH, Birbara CA, et al. Adalimumab, a fully human
anti-tumor necrosis factor alpha monoclonal antibody, for the
treatment of rheumatoid arthritis in patients taking
concomitant methotrexate: the ARMADA trial. Arthritis
Rheum 2003; 48: 35-45.
164.Keystone E, Heijde D, Mason D Jr, Landewé R,
Vollenhoven RV, Combe B, et al. Certolizumab pegol plus
methotrexate is significantly more effective than placebo plus
methotrexate in active rheumatoid arthritis: findings of a fifty-
two-week, phase III, multicenter, randomized, double-blind,
placebo-controlled, parallel-group study. Arthritis Rheum
2008;58:3319-29.
165.Pincus T, Furer V, Keystone E, Yazici Y, Bergman MJ,
Luijtens K. RAPID3 (Routine Assessment of Patient Index Data
3) severity categories and response criteria: Similar results to
DAS28 (Disease Activity Score) and CDAI (Clinical Disease
Activity Index) in the RAPID 1 (Rheumatoid Arthritis
Prevention of Structural Damage) clinical trial of certolizumab
pegol. Arthritis Care Res (Hoboken) 2011;63:1142-9.
166.van Vollenhoven RF, Felson D, Strand V, Weinblatt ME,
Luijtens K, Keystone EC. American College of Rheumatology
hybrid analysis of certolizumab pegol plus methotrexate in
patients with active rheumatoid arthritis: data from a 52-week
phase III trial. Arthritis Care Res (Hoboken) 2011; 63:128-34.
167.Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP,
Kvien TK, et al. Etanercept and sulfasalazine, alone and